We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quartz Bio Supports Debiopharm Group Precision Medicine Bioinformatics
News

Quartz Bio Supports Debiopharm Group Precision Medicine Bioinformatics

Quartz Bio Supports Debiopharm Group Precision Medicine Bioinformatics
News

Quartz Bio Supports Debiopharm Group Precision Medicine Bioinformatics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Quartz Bio Supports Debiopharm Group Precision Medicine Bioinformatics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Debiopharm Group™ has announced that they have signed a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery.

Under the research framework, Quartz Bio will apply its leading expertise in bioinformatics to support Debiopharm translational projects in terms of computational analyses and biomarker discovery.

Projects are expected to range from preclinical Next-Generation Sequencing to clinical biomarker data analyses.

“We are delighted to collaborate with Debiopharm,” said Dr. Jerome Wojcik, CEO of Quartz Bio. “Debiopharm’s pioneering biomarker projects are a unique opportunity for Quartz Bio to contribute to the implementation of Precision Medicine, thus demonstrating that bioinformatics science can bring substantial benefits to patients”.

“We look forward to collaborating with Quartz Bio,” commented Dr. Hiroaki Tanaka, Director of Personalized Medicine at Debiopharm.

Dr. Tanaka continued, “Their longstanding clinical bioinformatics experience made them an ideal partner to support our biomarker projects in our clinical trials and extract from data the relevant information required for personalized therapy development”.

Advertisement